Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 4 Antibiotic consumption

From: Efficacy of an antimicrobial stewardship intervention for early adaptation of antibiotic therapy in high-risk neutropenic patients

 

Pre-intervention period (n = 56)

Intervention period (n = 57)

p value

DOT/1000 hospital days, n

860

648

 

DDD/1000 hospital days, n

1216

946

 

Overall antibiotic DOT

28 (20.75–40)

20 (10–32)

0.006

LOT

21 (14–24.25)

15 (8–23)

0.006

Antibiotic-free days

0 (0–0)

2 (0–8)

< 0.001

Aminoglycosides, n (%)

20 (36)

16 (28)

 

 DOT

1 (1–1)

1 (1–1)

0.553

Carbapenems, n (%)

26 (46)

20 (35)

 

 DOT

9 (6.25–15.25)

5.5 (4–8)

0.017

Piperacillin-tazobactam, n (%)

55 (98)

49 (86)

 

 DOT

14 (8–21.5)

10 (6–17)

0.084

Cefepime, n (%)

4 (7)

20 (35)

 

 DOT

6.5 (5–10.5)

7.5 (4–10)

0.953

Piperacillin-tazobactam/Cefepime/Aztreonam, n (%)

56 (100)

56 (98)

 

 DOT

14.5 (8–22)

12.5 (8–20)

0.61

Quinolones, n (%)

5 (9)

5 (9)

 

 DOT

3 (2–8)

4 (2–8)

0.733

Anti-resistant Gram-positive agents, n (%)

36 (64)

36 (63)

 

 DOT

11.5 (7–18)

8 (4–12)

0.017

  1. Data are presented as median (interquartile range) unless otherwise indicated
  2. DOT and LOT are expressed in days
  3. Anti-resistant Gram-positive agents include glycopeptides, lipopeptides and oxazolidinones
  4. Abbreviations: DDD: Defined daily dose; DOT: Days of therapy; LOT: Length of therapy